November 1994
Volume 35, Issue 12
Free
Articles  |   November 1994
Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model.
Author Affiliations
  • Y J Gordon
    Charles T. Campbell Laboratory, Eye and Ear Institute of Pittsburgh, Pennsylvania 15213.
  • E G Romanowski
    Charles T. Campbell Laboratory, Eye and Ear Institute of Pittsburgh, Pennsylvania 15213.
  • T Araullo-Cruz
    Charles T. Campbell Laboratory, Eye and Ear Institute of Pittsburgh, Pennsylvania 15213.
Investigative Ophthalmology & Visual Science November 1994, Vol.35, 4135-4143. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y J Gordon, E G Romanowski, T Araullo-Cruz; Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model.. Invest. Ophthalmol. Vis. Sci. 1994;35(12):4135-4143.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: To evaluate the antiviral inhibitory activity of HPMPC against ocular adenoviral serotypes in vitro and to determine the therapeutic efficacy and ocular toxicity of treatment with topical HPMPC on established adenovirus type 5 (AD5) McEwen infection in the New Zealand (NZ) rabbit ocular replication model. METHODS: The 50% inhibitory dose (ID50) of HPMPC was determined for various clinical isolates of AD5 and AD8 by plaque assay in A549 cells. In vivo inhibitory effects were measured by serial ocular titers and duration of viral shedding in the AD5-NZ rabbit ocular model. Local ocular toxicity was evaluated by external and slit lamp examination for blepharitis, conjunctivitis, keratitis, and iritis. RESULTS: The mean ID50 for seven isolates of AD8 was 0.47 (range, 0.02 microgram/ml to 0.82 microgram/ml), and the mean ID50 for seven isolates of AD5 was 1.03 (range, 0.15 microgram/ml to 2.80 micrograms/ml). In a series of in vivo experiments, topical administration of HPMPC for as long as 10 days (total dose, > 2.8 mg) significantly reduced both AD5 ocular titers and the number of days of viral shedding compared to that for vehicle-treated control eyes. Local ocular toxicity was not clinically significant at a total dose of < 10 mg administered for as long as 10 days. CONCLUSIONS: HPMPC, a broad-spectrum, long-acting nucleoside monophosphate analog, is a promising candidate for the treatment of epidemic keratoconjunctivitis infections. Further studies to ensure safety and efficacy in humans are warranted.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×